Use of CHROMagar Candida for the presumptive identification of Candida species directly from clinical specimens in resource-limited settings

Libyan Journal of Medicine

Volumn 5, Issue 1, 2010, Pages 1-6

  Nadeem, Sayyada Ghufrana ^a,b   Hakim, Shazia Tabassum ^a   Kazmi, Shahana Urooj ^b  

^a JINNAH UNIVERSITY FOR WOMEN   (Pakistan)

^b UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

CHROMagar Candida; Presumptive identification; Resource limited settings

Indexed keywords

AGAR MEDIUM; ARTICLE; BIOCHEMISTRY; CANDIDA ALBICANS; CANDIDA KRUSEI; CANDIDA TROPICALIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FUNGAL COLONIZATION; FUNGAL MORPHOLOGY; FUNGAL STRAIN; FUNGUS IDENTIFICATION; NONHUMAN; SENSITIVITY AND SPECIFICITY;

EID: 77951192835     PISSN: 19932820     EISSN: 18196357     Source Type: Journal    
DOI: 10.3402/ljm.v5i0.2144     Document Type: Article

References (33)

1. Fraser VJ, Jones M, Dunkel J, Storfer S, Medoff G, Dunagan WC. Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. J Clin Infect Dis. 1992; 15: 415-21.
2. Price MF, La Rocco MT, Gentry LO. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period. J Antimicrob Agents Chemother. 1994; 38: 1422-4.
3. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis. 1995; 20: 115-25.
4. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980 1990. J Infect Dis. 1993; 167: 1247-51.
5. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980 1997. J Clin Infect Dis. 2001; 33: 641-7.
6. Patterson TF. Invasive mycoses: management and unmet medical needs. Curr Opin J Infect Dis. 2001; 14: 669-71.
7. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment of invasive fusariosis in patients with underlying hematologic malignancy and other conditions. J Clin Infect Dis. 2006; 42: 1398-403.
8. Yasuda JM. An update on antifungal therapy: a focus on systemic agents for invasive fungal infections. Calif J Health Syst Pharm. 2001; 13: 4-12.
9. Beck-Sague C, Jarvis WR. National nosocomial infections surveillance system: secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980 1990. J Infect Dis. 1993; 167: 1247-51.
10. Rangel-Frausto MS, Wiblin T, Blumberg HM, Saiman L, Patterson J, Rinaldi M, et al. National Epidemiology of Mycoses Survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. Clin Infect Dis. 1999; 29: 253-8.
11. Michael A. Pfaller. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. J Clin Infect Dis. 1996; 22: S89-S94.
12. Pfaller M, Cabezudo I, Koontz F, Bale M, Gingrich R. Predictive value of surveillance cultures for systemic infection due to Candida species. Eur J Clin Microbiol. 1987; 6: 628-33, 37.
13. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of non neutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob Agents Chemother. 1995; 39: 40-4.
14. Sandford GR, Merz WG, Wingard JR, Charache P, Saral R. The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis. 1980; 142: 503-9.
15. Magee BB, Magee PT. Recent advances in the genomic analysis of Candida albicans. Rev Iberoam Micol. 2005; 22: 187-93.
16. Pontion J, Ruckehl R, Clemons KV, Coleman DC, Grillot R, Guarro J, et al. Emerging pathogens. Med Mycol. 2000; 38: 225-36.
17. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. J Clin Microbiol Rev. 1996; 9: 499-511.
18. Hospenthal DR, Murray CK, Rinaldi MG. The role of antifungal susceptibility testing in the therapy of candidiasis. J Diagn Microbiol Infect Dis. 2004; 48: 153-60.
19. Freydiere AM, Guinet R, Boiron P. Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med Mycol. 2001; 39: 9-33.
20. Murray CK, Beckius ML, Green JA, Hospenthal DR. Use of chromogenic medium in the isolation of yeasts from clinical specimens. J Med Microbiol. 2005; 54: 981-5.
21. Maertens JA. History of the development of azole derivatives. J Clin Microbiol Infect. 2004; 10: 1-10.
22. Fenn JP, Segal H, Barland B, Denton D, Whisenant J, Chun H, et al. Comparison of updated Vitek yeast biochemical card and API 20C yeast identification systems. J Clin Microbiol. 1994; 32: 1184-7.
23. Heelan JS, Sotomayor E, Coon K, D'Arezzo JB. Comparison of the rapid yeast plus panel with the API20C yeast system for identification of clinically significant isolates of Candida species. J Clin Microbiol. 1998; 36: 1443-5.
24. Kitch TT, Jacobs MR, McGinnis MR, Applebaum PC. Ability of RapID Yeast Plus System to identify 304 clinically significant yeasts within 5 hours. J Clin Microbiol. 1996; 34: 1069-71.
25. Marler JK, Eriquez LA. Comparison of the IDS RapID Yeast Plus System and the API 20C for the identification of medically important yeast. Proceedings of the 95th General Meeting of the American Society for Microbiology, Washington, DC, 1995; abstr. C-418, p. 73.
26. Schuffenecker I, Freydiere A, de Montclos H, Gille Y. Evaluation of four commercial systems for identification of medically important yeasts. Eur J Clin Microbiol Infect Dis. 1993; 12: 255-60.
27. http://www.chromagar.com
28. Baumgartner C, Freydiere A, Gille Y. Direct identification and recognition of yeast species from clinical material by using Albicans ID and CHROMagar Candida plates. J Clin Microbiol. 1996; 34: 454-6.
29. Bernal S, Mazuelos EM, Garcia M, Aller AI, Martinez MA, Gutierrez MJ. Evaluation of CHROMagar Candida medium for isolation and presumptive identification of species of Candida of clinical importance. Diagn Microbiol Infect Dis. 1996; 24: 201-4.
30. Huang L, Chen C, Chou C, Lu J, Chi W, Lee W. A comparison of methods for yeast identification including CHROMagar Candida, vitek system YBC and a traditional biochemical method. Chin Med J. 2001; 64: 568-74.
31. Odds FC, Bernaerts R. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J Clin Microbiol. 1994; 32: 1923-9.
32. Pfaller MA, Houston A, Coffmann S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei, and Candida (Torulopsis) glabrata. J Clin Microbiol. 1996; 34: 58-6.
33. Willinger B, Manafi M. Evaluation of CHROMagar Candida for rapid screening of clinical specimens for Candida species. Mycoses 1999; 42: 61-5.